ProfileGDS5678 / 1448761_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 81% 85% 82% 82% 84% 81% 83% 85% 83% 82% 82% 80% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9570383
GSM967853U87-EV human glioblastoma xenograft - Control 25.8577981
GSM967854U87-EV human glioblastoma xenograft - Control 36.3171785
GSM967855U87-EV human glioblastoma xenograft - Control 46.0446382
GSM967856U87-EV human glioblastoma xenograft - Control 55.9301482
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0701284
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6808981
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0082483
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3750185
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1728283
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9746682
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9406482
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6127180
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0366883